A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma

OBJECTIVE: To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. DESIGN: Phase 1 dose-escalation clinical trial. SETTING: Comprehensi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arch Neurol
Autori principali: Nabors, Louis B., Fiveash, John B., Markert, James M., Kekan, Manasi S., Gillespie, George Y., Huang, Zhi, Johnson, Martin J., Meleth, Sreelatha, Kuo, Huichien, Gladson, Candece L., Fathallah-Shaykh, Hassan M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120585/
https://ncbi.nlm.nih.gov/pubmed/20212229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.16
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi